Beijing Aosaikang’s ASKB589 Shows Promise in Phase I/II Study for Gastric Cancer
China’s Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has unveiled the latest results from a...
Biogen’s Higher-Dose Spinraza Regimen Under Review by FDA and EMA
US-based biopharmaceutical company Biogen (NASDAQ: BIIB) has submitted supplemental New Drug Applications (sNDAs) to the...
Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease
Denmark-based Novo Nordisk A/S (NYSE: NVO) has entered into a strategic collaboration and license agreement...
Zai Lab’s ZL-1310 Granted Orphan Drug Designation by FDA for SCLC
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced that the US Food...
Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies
Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has expanded its...
Johnson & Johnson Reports Q4 Growth, Projects 2025 Sales Outlook
US-based Johnson & Johnson (J&J, NYSE: JNJ) has released its Q4 2024 financial results, reporting...
YolTech Initiates Study for YOLT-204 in Transfusion-Dependent Beta-Thalassemia
Shanghai-based YolTech Therapeutics, a biotech startup specializing in lipid nanoparticle delivery and gene editing, has...
Haichang Bio’s siRNA Drug HC016 Cleared for US Clinical Trials
China-based Zhejiang Haichang Biotech Co., Ltd has announced that its siRNA drug, HC016 complex lipid,...
iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies
Hangzhou-based cell therapy specialist iMBIORAY has reportedly raised close to RMB 100 million (USD 13.7...
Abbott Labs Posts Q4 Growth, Projects Strong 2025 Outlook
US-based Abbott Laboratories (NYSE: ABT) has released its Q4 2024 financial results, reporting an 8.8%...
Shenzhen TargetRx Raises $50M in Series C Financing for Global Clinical Trials
China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, has announced the completion of...
Haisco’s HSK44459 Approved for Clinical Trials in Behcet’s Disease
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving clinical trial approval from...
Fosun’s Plan to Take Henlius Private Fails After Shareholder Vote
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its plan...
Belief BioMed’s BBM-D101 Receives FDA Approval for DMD Clinical Trial
China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced receiving clinical trial approval from...
Roche’s cobas liat STI Assay Panels Gain FDA Approval and CLIA Waiver
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced receiving approval from the US...
United Laboratories’ UBT251 Approved for Phase II Trials in Chronic Kidney Disease
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced receiving approval from the...
Sanofi’s Sarclisa Approved in EU for Newly Diagnosed Multiple Myeloma
France-based Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving marketing approval in the European Union...
Eli Lilly and Merck Launch Consortium for Innovative Drug Manufacturing
US-based Eli Lilly and Company (NYSE: LLY) and Merck & Co. Inc. (NYSE: MRK) have...
Akeso Biopharma Receives Development Payment for PD-L1 Monoclonal Antibody
China-based Akeso Biopharma (HKG: 9926) has announced receiving a drug collaboration development payment from compatriot...
Shanghai Bao Pharmaceuticals Launches IPO to Advance Biopharmaceutical Pipeline
China-based Shanghai Bao Pharmaceuticals Co., Ltd., a high-end biopharmaceuticals developer, has announced its initial public...